Physician

Lingyi Chen, M.D.

According to 2025 Medicare claims, Lingyi Chen, M.D. (NPI: 1922330844) practices internal medicine in the Hot Springs, AR market, with the plurality of this provider's patient population coming from Garland, AR. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 71913-6456.

Chen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 937 traditional Medicare patients, billed 306,927 HCPCS/CPT codes, and received $4,694,407 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,601 prescription claims across 273 beneficiaries totaling $3,486,814 in drug costs, led by Revlimid (Lenalidomide). DME data shows 75 claims. Open Payments data shows 193 records totaling $3,614. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $49,138 to $4,694,407. Similarly, Part D prescription costs have moved sharply higher in recent years, from $232,295 to $3,486,814. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,531 and ending at $523.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	140	443	$49,138
2016	249	4,084	$81,919
2017	563	163,498	$1,297,438
2018	599	223,826	$2,009,102
2019	643	276,985	$2,804,812
2020	701	265,636	$3,480,015
2021	855	270,980	$3,106,258
2022	821	303,814	$3,722,997
2023	803	248,661	$3,000,513
2024	937	306,927	$4,694,407

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	100	623	$232,295
2016	107	763	$497,157
2017	162	701	$741,666
2018	191	906	$1,181,091
2019	205	1,180	$1,393,439
2020	206	1,381	$1,547,201
2021	271	1,560	$1,873,498
2022	275	1,454	$2,618,327
2023	285	1,442	$2,622,150
2024	273	1,601	$3,486,814

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	39	$885
2017	N/R	11	$668
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	68	$4,081
2021	N/R	24	$1,438
2022	N/R	43	$2,966
2023	N/R	103	$15,082
2024	N/R	75	$2,818

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	292	675	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	615	1,709	$60
96372	Injection of drug or substance under skin or into muscle	256	1,214	$9
36415	Insertion of needle into vein for collection of blood sample	777	2,683	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	696	2,260	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	41	1,141	$558,233
Calquence	Acalabrutinib Maleate	39	1,170	$553,188
Lumakras	Sotorasib	12	360	$258,457
Brukinsa	Zanubrutinib	17	510	$244,035
Imbruvica	Ibrutinib	11	330	$192,699

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	20	$1,530
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$623
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$489
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	193	$3,614	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lingyi Chen, M.D.?

Tedicare shows public-source Medicare data for Lingyi Chen, M.D. (NPI 1922330844), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lingyi Chen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lingyi Chen, M.D.?

Lingyi Chen, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Lingyi Chen, M.D. have Open Payments data?

Lingyi Chen, M.D. has 193 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.